Time to onset of effect of fluticasone propionate in patients with asthma

被引:43
作者
Szefler, SJ
Boushey, HA
Pearlman, DS
Togias, A
Liddle, R
Furlong, A
Shah, T
Knobil, K
机构
[1] Natl Jewish Med & Res Ctr, Denver, CO USA
[2] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[3] Univ Calif San Francisco, Asthma Clin Res Ctr, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Allergy & Immunol, San Francisco, CA 94143 USA
[5] Colorado Allergy & Asthma Ctr, PC, Denver, CO USA
[6] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA
[7] Glaxo Wellcome Inc, US Med Affairs, Res Triangle Pk, NC 27709 USA
关键词
fluticasone propionate; asthma; glucocorticoid; onset; peak expiratory flow; FEV1;
D O I
10.1016/S0091-6749(99)70420-3
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The effectiveness of inhaled glucocorticoids in the treatment of asthma is well documented; however, times to onset and maximal treatment effects of these agents have been poorly described, Objective: We sought to determine the time to onset of effect and the time to the best observed effect of inhaled fluticasone propionate (FP) in patients with asthma, Methods: Data from 8 randomized; double-blind, placebo-controlled clinical trials of at least 8 weeks' duration were analyzed. Corticosteroid-naive patients (n = 1461) were treated with either FP (25 mu g to 500 mu g) or placebo twice daily. Efficacy evaluations included morning peak expiratory flow (PEF), asthma symptom scores, supplemental albuterol use, and FEV1, Results: Statistically significant improvements in PEF, asthma symptom scores, and supplemental albuterol use were observed beginning on day 1 of treatment in the FP group versus the placebo group (P < .001); significant increases in FEV1 were observed at the first measurement at week 1 (P < .001). The best observed effect occurred within 3 weeks of the start of FP treatment for PEF (+36 L/min) and FEV1 (+0.52 L) and within 2 weeks for reduction in supplemental albuterol use and asthma symptom scores. Patients with the most severe airflow obstruction had the greatest change in PEF (+56 L/min) and fastest time to 50% of best observed effect (3 days) compared with patients with-mild or moderate airflow obstruction; however, time to best observed effect was similar in the 3 groups (20 to 27 days). Conclusion: In patients with asthma, the onset of significant benefit of FP on PEF, symptoms, and rescue albuterol use occurred within 1 day of the start of therapy FEV1 improved within 1 week of the start; of therapy (the first measurement after randomization), There was no effect of sex, age, or dose of FP on the time to response. The best observed response in PEF varies with the degree of baseline airflow obstruction; however, the degree of airflow obstruction has no effect on the time to best observed response.
引用
收藏
页码:780 / 788
页数:9
相关论文
共 19 条
  • [1] [Anonymous], 1987, AM REV RESPIR DIS, V136, P225
  • [2] ARKY R, 1997, PHYSICIANS DESK REFE, P1004
  • [3] FLUTICASONE PROPIONATE AEROSOL FOR THE TREATMENT OF ADULTS WITH MILD-TO-MODERATE ASTHMA
    CHERVINSKY, P
    VANAS, A
    BRONSKY, EA
    DOCKHORN, R
    NOONAN, M
    LAFORCE, C
    PLESKOW, W
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (04) : 676 - 683
  • [4] Airways remodeling is a distinctive feature of asthma and is related to severity of disease
    Chetta, A
    Foresi, A
    DelDonno, M
    Bertorelli, G
    Pesci, A
    Olivieri, D
    [J]. CHEST, 1997, 111 (04) : 852 - 857
  • [5] CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659
  • [6] Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo
    Esmailpour, N
    Hogger, P
    Rabe, KF
    Heitmann, U
    Nakashima, M
    Rohdewald, P
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1496 - 1499
  • [7] THE HUMAN PHARMACOLOGY OF FLUTICASONE PROPIONATE
    HARDING, SM
    [J]. RESPIRATORY MEDICINE, 1990, 84 : 25 - 29
  • [8] INHALED FLUTICASONE PROPIONATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN ASTHMA
    HOLLIDAY, SM
    FAULDS, D
    SORKIN, EM
    [J]. DRUGS, 1994, 47 (02) : 318 - 331
  • [9] Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids
    Johnson, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (01) : 169 - 176
  • [10] HIGH-DOSE SYSTEMIC GLUCOCORTICOID THERAPY IN THE TREATMENT OF SEVERE ASTHMA - A CASE OF RESISTANCE AND PATTERNS OF RESPONSE
    KAMADA, AK
    LEUNG, DYM
    GLEASON, MC
    HILL, MR
    SZEFLER, SJ
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 90 (04) : 685 - 687